{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:46:30Z","timestamp":1792273590549,"version":"4.4.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374420"],"award-info":[{"award-number":["82374420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02397-1","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:02:40Z","timestamp":1792263760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-associated myocarditis: clinical and mechanistic insights"],"prefix":"10.1007","volume":"75","author":[{"given":"Heng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjing","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"5","key":"2397_CR1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2397_CR2","volume":"3","author":"A Haslam","year":"2020","unstructured":"Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3(3):e200423.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2397_CR3","doi-asserted-by":"crossref","first-page":"e70176","DOI":"10.1002\/mco2.70176","volume":"6","author":"Z Chen","year":"2025","unstructured":"Chen Z, Song Z, Den S, Zhang W, Han M, Lan T, et al. Application of immune checkpoint inhibitors in cancer. MedComm. 2025;6(8):e70176.","journal-title":"MedComm"},{"issue":"1","key":"2397_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","volume":"18","author":"L Huang","year":"2025","unstructured":"Huang L, Zhu H, Shi Y. Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025). J Hematol Oncol. 2025;18(1):107.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2397_CR5","doi-asserted-by":"crossref","first-page":"Itc17","DOI":"10.7326\/AITC202402200","volume":"177","author":"M Ramos-Casals","year":"2024","unstructured":"Ramos-Casals M, Sis\u00f3-Almirall A. Immune-related adverse events of immune checkpoint inhibitors. Ann Intern Med. 2024;177(2):Itc17-itc32.","journal-title":"Ann Intern Med"},{"issue":"29","key":"2397_CR6","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"AR Naqash","year":"2022","unstructured":"Naqash AR, Moey MYY, Tan X-WC, Laharwal M, Hill V, Moka N, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program. J Clin Oncol. 2022;40(29):3439\u201352.","journal-title":"J Clin Oncol"},{"issue":"29","key":"2397_CR7","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40(29):3430\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2397_CR8","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","volume":"26","author":"CG Tocchetti","year":"2024","unstructured":"Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024;26(10):2055\u201376.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2397_CR9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1042\/CS20200331","volume":"135","author":"AH Baik","year":"2021","unstructured":"Baik AH, Tsai KK, Oh DY, Aras MA. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond). 2021;135(5):703\u201324.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"2397_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaccao.2025.03.001","volume":"7","author":"D Idossa","year":"2025","unstructured":"Idossa D, Herrmann J, Ruddy KJ. Outcomes and predictors of severity of immunotherapy-related myocarditis. JACC CardioOncol. 2025;7(3):249\u201351.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"2397_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80\u201391.","journal-title":"Circulation"},{"issue":"8041","key":"2397_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","volume":"636","author":"SM Blum","year":"2024","unstructured":"Blum SM, Zlotoff DA, Smith NP, Kernin IJ, Ramesh S, Zubiri L, et al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature. 2024;636(8041):215\u201323.","journal-title":"Nature"},{"issue":"8","key":"2397_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","volume":"24","author":"AZ Munir","year":"2024","unstructured":"Munir AZ, Gutierrez A, Qin J, Lichtman AH, Moslehi JJ. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Nat Rev Cancer. 2024;24(8):540\u201353.","journal-title":"Nat Rev Cancer"},{"key":"2397_CR14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2025.12.004","volume":"119","author":"Y Chen","year":"2026","unstructured":"Chen Y, Wang X, Shen Y, Zhang H, Yu C, Cheng L, et al. Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics. Semin Cancer Biol. 2026;119:12\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2397_CR15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, et al. NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024;22(9):582\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"2397_CR16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"48","key":"2397_CR17","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42(48):4964\u201377.","journal-title":"Eur Heart J"},{"issue":"10","key":"2397_CR18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","volume":"10","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol. 2024;10(10):1390\u20139.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2397_CR19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","volume":"12","author":"J Herrmann","year":"2026","unstructured":"Herrmann J, Barac A, Carver J, Cheng RK, Daniele A, Dent S, et al. Immune checkpoint inhibitor-associated cardiovascular toxic effects: international Cardio-Oncology Society position statement. JAMA Oncol. 2026;12(1):90\u20139.","journal-title":"JAMA Oncol"},{"issue":"9","key":"2397_CR20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","volume":"47","author":"JE Salem","year":"2026","unstructured":"Salem JE, Ajrouche A, Rozes A, Pinto S, De Rycke Y, Tubach F. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur Heart J. 2026;47(9):1014\u201330.","journal-title":"Eur Heart J"},{"issue":"6","key":"2397_CR21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213\u201327.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2397_CR22","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"2397_CR23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"key":"2397_CR24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024;70:102536.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"2397_CR25","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. 2023;29(12):3100\u201310.","journal-title":"Nat Med"},{"issue":"2","key":"2397_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.6004\/jadpro.2024.15.2.4","volume":"15","author":"SM Otto","year":"2024","unstructured":"Otto SM, Martinez AL, Dains JE. Risk factors for immune checkpoint inhibitor-related myocarditis: an integrative review. J Adv Pract Oncol. 2024;15(2):111\u201323.","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"2397_CR27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaccao.2022.11.008","volume":"4","author":"C Lee","year":"2022","unstructured":"Lee C, Drobni ZD, Zafar A, Gongora CA, Zlotoff DA, Alvi RM, et al. Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy. JACC CardioOncol. 2022;4(5):660\u20139.","journal-title":"JACC CardioOncol"},{"issue":"11","key":"2397_CR28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","volume":"5","author":"Y Zamami","year":"2019","unstructured":"Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5(11):1635\u20137.","journal-title":"JAMA Oncol"},{"issue":"669","key":"2397_CR29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1981","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, et al. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022;14(669):eabo1981.","journal-title":"Sci Transl Med"},{"issue":"42","key":"2397_CR30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2323052121","volume":"121","author":"H Kalinoski","year":"2024","unstructured":"Kalinoski H, Daoud A, Rusinkevich V, Jur\u010dov\u00e1 I, Talor MV, Welsh RA, et al. Injury-induced myosin-specific tissue-resident memory T cells drive immune checkpoint inhibitor myocarditis. Proc Natl Acad Sci U S A. 2024;121(42):e2323052121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2397_CR31","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.172.4.2651","volume":"172","author":"JA Taylor","year":"2004","unstructured":"Taylor JA, Havari E, McInerney MF, Bronson R, Wucherpfennig KW, Lipes MA. A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J Immunol. 2004;172(4):2651\u20138.","journal-title":"J Immunol"},{"issue":"3-4","key":"2397_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaut.2009.09.005","volume":"33","author":"V Taneja","year":"2009","unstructured":"Taneja V, David CS. Spontaneous autoimmune myocarditis and cardiomyopathy in HLA-DQ8.NODAbo transgenic mice. J Autoimmun. 2009;33(3\u20134):260\u20139.","journal-title":"J Autoimmun"},{"key":"2397_CR33","doi-asserted-by":"crossref","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, E.S.C.S.D. Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43(41):4229\u20134361","DOI":"10.1714\/3967.39463"},{"issue":"4","key":"2397_CR34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"key":"2397_CR35","doi-asserted-by":"crossref","unstructured":"Schulz-Menger J, Collini V, Gr\u00f6schel J, Adler Y, Brucato A, Christian V, Ferreira VM, Gandjbakhch E, Heidecker B, Kerneis M, Klein AL, Klingel K, Lazaros G, Lorusso R, Nesukay EG, Rahimi K, Risti\u0107 AD, Rucinski M, Sade LE, Schaubroeck H, Semb AG, Sinagra G, Thune JJ, Imazio M, E.S.C.S.D.G. the, 2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC)Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2025;46(40):3952\u20134041","DOI":"10.1093\/eurheartj\/ehaf192"},{"issue":"1","key":"2397_CR36","first-page":"3","volume":"1","author":"HT Aretz","year":"1987","unstructured":"Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, et al. Myocarditis A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1(1):3\u201314.","journal-title":"Am J Cardiovasc Pathol"},{"key":"2397_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-pharmtox-010919-023451","volume":"61","author":"S Waliany","year":"2021","unstructured":"Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, et al. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol. 2021;61:113\u201334.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"2397_CR38","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2397_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","volume":"33","author":"SN Champion","year":"2020","unstructured":"Champion SN, Stone JR. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol. 2020;33(1):99\u2013108.","journal-title":"Mod Pathol"},{"key":"2397_CR40","doi-asserted-by":"crossref","unstructured":"Nishikawa T, Otani T, Yamamoto H, Yasui T, Shingu M, Osumi Y, Ishibashi K, Ikeda Y, Nonaka A, Fukuda Y, Murai R et al. Novel insights into the histopathological characteristics of immune checkpoint inhibitor-related myocarditis. ESC Heart Fail. 2026;13(3).","DOI":"10.1093\/eschf\/xvag153"},{"issue":"1","key":"2397_CR41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circ. 2024;149(1):48\u201366.","journal-title":"Circ"},{"issue":"1","key":"2397_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.123.067189","volume":"149","author":"D Cihakova","year":"2024","unstructured":"Cihakova D. T cells and macrophages drive pathogenesis of immune checkpoint inhibitor myocarditis. Circ. 2024;149(1):67\u20139.","journal-title":"Circ"},{"issue":"5","key":"2397_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s44161-025-00640-2","volume":"4","author":"RG Fankhauser","year":"2025","unstructured":"Fankhauser RG, Johnson DB, Moslehi JJ, Balko JM. Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis. Nat Cardiovasc Res. 2025;4(5):526\u201338.","journal-title":"Nat Cardiovasc Res"},{"issue":"2","key":"2397_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","volume":"120","author":"L Vermeulen","year":"2020","unstructured":"Vermeulen L, Depuydt CE, Weckx P, Bechter O, Van Damme P, Thal DR, et al. Myositis as a neuromuscular complication of immune checkpoint inhibitors. Acta Neurol Belg. 2020;120(2):355\u201364.","journal-title":"Acta Neurol Belg"},{"issue":"18","key":"2397_CR45","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"7937","key":"2397_CR46","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326.","journal-title":"Nature"},{"key":"2397_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113319","volume":"194","author":"J Abitbol","year":"2023","unstructured":"Abitbol J, Vallet A, Routier E, Smaali S, Robert C. Immune checkpoint inhibitors-associated myocarditis without cardiovascular symptoms. Eur J Cancer. 2023;194:113319.","journal-title":"Eur J Cancer"},{"key":"2397_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002553","author":"I Puzanov","year":"2021","unstructured":"Puzanov I, Subramanian P, Yatsynovich YV, Jacobs DM, Chilbert MR, Sharma UC, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002553.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2397_CR49","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","volume":"5","author":"O Itzhaki Ben Zadok","year":"2023","unstructured":"Itzhaki Ben Zadok O, Levi A, Divakaran S, Nohria A. Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes. JACC Cardio Oncol. 2023;5(6):732\u201344.","journal-title":"JACC Cardio Oncol"},{"issue":"24","key":"2397_CR50","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299\u2013311.","journal-title":"Circulation"},{"key":"2397_CR51","doi-asserted-by":"crossref","unstructured":"Chen Z, Zheng M, Li Y, Zhang X, Dou J. Immune checkpoint inhibitor-associated cardiovascular toxicity: mechanisms, clinical manifestations, and clinical impact. Cardiovasc Toxicol. 2026;26(6).","DOI":"10.1007\/s12012-026-10131-w"},{"issue":"6","key":"2397_CR52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473\u201386.","journal-title":"Circulation"},{"issue":"5","key":"2397_CR53","first-page":"624","volume":"4","author":"F Thuny","year":"2022","unstructured":"Thuny F, Bonaca Marc P, Cautela J. What Is the evidence of the diagnostic criteria and screening of immune checkpoint inhibitor-induced myocarditis? JACC: Cardio Oncol. 2022;4(5):624\u20138.","journal-title":"JACC: Cardio Oncol"},{"key":"2397_CR54","doi-asserted-by":"crossref","first-page":"1800066","DOI":"10.3389\/fcvm.2026.1800066","volume":"13","author":"AJ Alaraibi","year":"2026","unstructured":"Alaraibi AJ, Alani M, Al-Nooh L, Quateen N, Al-Qallaf L, Al-Azemi R, et al. Troponin for surveillance of immune checkpoint inhibitor-associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis. Front Cardiovasc Med. 2026;13:1800066.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"2397_CR55","first-page":"804","volume":"6","author":"A Barac","year":"2024","unstructured":"Barac A, Wadlow Raymond C, Deeken John F, deFilippi C. Cardiac troponin I and T in ICI myocarditis screening Diagnosis, and Prognosis. JACC: Cardio Oncol. 2024;6(5):804\u20137.","journal-title":"JACC: Cardio Oncol"},{"issue":"16","key":"2397_CR56","doi-asserted-by":"crossref","first-page":"102462","DOI":"10.1016\/j.jaccas.2024.102462","volume":"29","author":"C Beaulieu","year":"2024","unstructured":"Beaulieu C, Wu Kai Y, F\u00fcz\u00e9ry Anna K, Raizman Joshua E, Tsui Albert KY, Ye C, et al. Elevated troponin T in immune-checkpoint inhibitor myositis. JACC Case Rep. 2024;29(16):102462.","journal-title":"JACC Case Rep"},{"issue":"5","key":"2397_CR57","first-page":"689","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, Gradone A, Azam Tariq U, Perry D, et al. Biomarker Trends, Incidence, and Outcomes of immune checkpoint inhibitor\u2013induced myocarditis. JACC: Cardio Oncol. 2022;4(5):689\u2013700.","journal-title":"JACC: Cardio Oncol"},{"key":"2397_CR58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.884776","volume":"13","author":"Y Nakagomi","year":"2022","unstructured":"Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y, et al. Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature. Front Pharmacol. 2022;13:884776.","journal-title":"Front Pharmacol"},{"key":"2397_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","author":"DN Lipe","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, Nguyen TD, Chaftari P, El Messiri N, et al. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024. https:\/\/doi.org\/10.3390\/diagnostics14161794.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"2397_CR60","first-page":"252","volume":"7","author":"O Itzhaki Ben Zadok","year":"2025","unstructured":"Itzhaki Ben Zadok O, O\u2019Hare Meabh J, Nohria A. Immune Checkpoint inhibitor-related myocarditis with or without concomitant myopathy. JACC: CardioOncology. 2025;7(3):252\u201364.","journal-title":"JACC: CardioOncology"},{"key":"2397_CR61","doi-asserted-by":"crossref","unstructured":"Blanco-Dom\u00ednguez R, S\u00e1nchez-D\u00edaz R, de la Fuente H, Jim\u00e9nez-Borreguero LJ, Matesanz-Mar\u00edn A, Rela\u00f1o M, Jim\u00e9nez-Alejandre R, Linillos-Pradillo B, Tsilingiri K, Mart\u00edn-Mariscal ML, Alonso-Herranz L. A novel circulating noncoding small RNA for the detection of acute myocarditis. N Engl J Med. 2021;384(21):2014\u20132027.","DOI":"10.1056\/NEJMoa2003608"},{"issue":"11","key":"2397_CR62","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s12094-023-03217-2","volume":"25","author":"E Zatarain-Nicol\u00e1s","year":"2023","unstructured":"Zatarain-Nicol\u00e1s E, Mart\u00edn P, M\u00e1rquez Rodas I, Virizuela J, Mart\u00edn Garc\u00eda A, Mitroi C, et al. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish immunotherapy registry of cardiovascular toxicity. Clin Transl Oncol. 2023;25(11):3073\u201385.","journal-title":"Clin Transl Oncol"},{"key":"2397_CR63","doi-asserted-by":"crossref","unstructured":"Pascual-Figal DA, Garc\u00eda-Serna AM, Esteban-Gil A, Fuster JJ, Mart\u00edn P, S\u00e1nchez-Cabo F, Uribarri A, Iniesta-Manjavacas AM, Larra\u00f1aga-Moreira JM, Lopez-Fernandez S, Pastor-Pueyo P. Rationale and design of the Pre-MYO project: a precision-medicine platform for myocarditis diagnosis and management. ESC Heart Fail. 2026;13(2).","DOI":"10.1093\/eschf\/xvag022"},{"key":"2397_CR64","doi-asserted-by":"crossref","unstructured":"Raissadati A, Zhou X, Chou H, Huang YV, Khatua S, Sun Y, Xu A, Loa S, Hernandez A, Zhu H, Wu SM. Using plasma cell-free mRNA to profile immune response and myocardial damage in immune checkpoint inhibitor-induced myocarditis. J Clin Invest. 2025;135(16).","DOI":"10.1172\/JCI188817"},{"issue":"Supplement_2","key":"2397_CR65","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.2711","volume":"44","author":"JC Heemelaar","year":"2023","unstructured":"Heemelaar JC, Quinaglia T, Drobni ZD, Ho J, Gilman HK, Zlotoff DA, et al. Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis. Eur Heart J. 2023;44(Supplement_2):ehad655.2711.","journal-title":"Eur Heart J"},{"issue":"2","key":"2397_CR66","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101478","volume":"48","author":"W Song","year":"2023","unstructured":"Song W, Zheng Y, Dong M, Zhong L, Bazoukis G, Perone F, et al. Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis. Curr Probl Cardiol. 2023;48(2):101478.","journal-title":"Curr Probl Cardiol"},{"key":"2397_CR67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jelectrocard.2024.153779","volume":"86","author":"W Song","year":"2024","unstructured":"Song W, Chen Z, Zheng Y, Xu Y, Sun Y, Zhao Z, et al. Clinical and electrocardiographic characteristics of immune checkpoint inhibitor-related myocarditis. J Electrocardiol. 2024;86:153779.","journal-title":"J Electrocardiol"},{"issue":"15","key":"2397_CR68","volume":"13","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang H, Qiu Y, Bian X, Wang X, Li Y. Early identification of severe immune checkpoint inhibitor associated myocarditis: from an electrocardiographic perspective. Cancer Med. 2024;13(15):e7460.","journal-title":"Cancer Med"},{"key":"2397_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002007","author":"DA Zlotoff","year":"2021","unstructured":"Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002007.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2397_CR70","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jacc.2006.08.017","volume":"48","author":"HN Skouri","year":"2006","unstructured":"Skouri HN, Dec GW, Friedrich MG, Cooper LT. Noninvasive imaging in myocarditis. J Am Coll Cardiol. 2006;48(10):2085\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2397_CR71","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2397_CR72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","volume":"75","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75(5):467\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2397_CR73","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jacc.2025.10.018","volume":"87","author":"S Ganatra","year":"2026","unstructured":"Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, et al. Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton\u2019s tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC concise clinical guidance: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2026;87(5):654\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2397_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11897-025-00717-w","volume":"22","author":"J-E Salem","year":"2025","unstructured":"Salem J-E, Baldassarre LA, Redheuil A, Boussouar S, Thavendiranathan P, Procureur A. Cardiac magnetic resonance imaging in immune checkpoint inhibitor\u2013myocarditis: diagnostic and prognostic evidence and limitations. Curr Heart Fail Rep. 2025;22(1):28.","journal-title":"Curr Heart Fail Rep"},{"issue":"24","key":"2397_CR75","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"2397_CR76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116693","volume":"239","author":"T Lerchner","year":"2026","unstructured":"Lerchner T, Buehning F, Vogel J, Mincu RI, Zimmer L, Tasdogan A, et al. Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: a meta-analysis. Eur J Cancer. 2026;239:116693.","journal-title":"Eur J Cancer"},{"issue":"17","key":"2397_CR77","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475\u201387.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2397_CR78","doi-asserted-by":"crossref","DOI":"10.3390\/jimaging8040099","volume":"8","author":"L Arcari","year":"2022","unstructured":"Arcari L, Tini G, Camastra G, Ciolina F, De Santis D, Russo D, et al. Cardiac magnetic resonance imaging in immune check-point inhibitor myocarditis: a systematic review. J Imaging. 2022;8(4):99.","journal-title":"J Imaging"},{"issue":"12","key":"2397_CR79","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor\u2013associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2397_CR80","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1148\/radiol.211765","volume":"303","author":"F Cadour","year":"2022","unstructured":"Cadour F, Cautela J, Rapacchi S, Varoquaux A, Habert P, Arnaud F, et al. Cardiac MRI features and prognostic value in immune checkpoint inhibitor\u2013induced myocarditis. Radiology. 2022;303(3):512\u201321.","journal-title":"Radiology"},{"key":"2397_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101249","author":"M Tysarowski","year":"2025","unstructured":"Tysarowski M, Khattab M, Zarif T, Kwan JM, Baldassarre LA. Prospective evaluation of ICI myocarditis: late gadolinium enhancement predicts mortality. J Cardiovasc Magn Reson. 2025. https:\/\/doi.org\/10.1016\/j.jocmr.2024.101249.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"Supplement_1","key":"2397_CR82","volume":"46","author":"T Lerchner","year":"2025","unstructured":"Lerchner T, Buehning F, Vogel J, Mincu R, Totzeck M, Rassaf T, et al. Cardiac magnetic resonance imaging for diagnosis and prognosis of patients with myocarditis from immune checkpoint inhibitor therapy: a meta-analysis. Eur Heart J. 2025;46(Supplement_1):ehaf784.4138.","journal-title":"Eur Heart J"},{"issue":"1","key":"2397_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22178-0","volume":"12","author":"J Sugita","year":"2021","unstructured":"Sugita J, Fujiu K, Nakayama Y, Matsubara T, Matsuda J, Oshima T, et al. Cardiac macrophages prevent sudden death during heart stress. Nat Commun. 2021;12(1):1910.","journal-title":"Nat Commun"},{"issue":"1","key":"2397_CR84","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-024-01840-1","volume":"9","author":"R Chen","year":"2024","unstructured":"Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9(1):130.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2397_CR85","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","volume":"10","author":"L Wang","year":"2025","unstructured":"Wang L, Liang Y, Zhao C, Ma P, Zeng S, Ju D, et al. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduct Target Ther. 2025;10(1):345.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2397_CR86","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/eji.200324270","volume":"33","author":"N Rodig","year":"2003","unstructured":"Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33(11):3117\u201326.","journal-title":"Eur J Immunol"},{"key":"2397_CR87","unstructured":"Yousif LI, Sijtema AG, Appels Y, van den Berg PF, Aboumsallem JP, Manintveld OC, Duncker DJ, de Boer RA, Meijers WC. PD-1\/PD-L1 signaling in non-ICI myocarditis. JACC: Basic Transl Sci."},{"issue":"4","key":"2397_CR88","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","volume":"43","author":"L Michel","year":"2022","unstructured":"Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43(4):316\u201329.","journal-title":"Eur Heart J"},{"issue":"1","key":"2397_CR89","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-021-01161-8","volume":"14","author":"W Qian","year":"2021","unstructured":"Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14(1):147.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2397_CR90","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"1","key":"2397_CR91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/83144","volume":"2","author":"LP Kane","year":"2001","unstructured":"Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol. 2001;2(1):37\u201344.","journal-title":"Nat Immunol"},{"issue":"6478","key":"2397_CR92","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/369327a0","volume":"369","author":"F Pag\u00e8s","year":"1994","unstructured":"Pag\u00e8s F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature. 1994;369(6478):327\u20139.","journal-title":"Nature"},{"issue":"4","key":"2397_CR93","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883\u201395.","journal-title":"J Exp Med"},{"key":"2397_CR94","volume":"112","author":"S Hu","year":"2020","unstructured":"Hu S, Liu X, Li T, Li Z, Hu F. LAG3 (CD223) and autoimmunity: emerging evidence. J Autoimmun. 2020;112:102504.","journal-title":"J Autoimmun"},{"issue":"1","key":"2397_CR95","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"issue":"6","key":"2397_CR96","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41(6):111611.","journal-title":"Cell Rep"},{"issue":"2","key":"2397_CR97","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ehf2.14614","volume":"11","author":"N Rubio-Infante","year":"2024","unstructured":"Rubio-Infante N, Castillo EC, Alves-Figueiredo H, Ramos-Gonz\u00e1lez M, Salazar-Ram\u00edrez F, Salas-Trevi\u00f1o D, et al. Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice. ESC Heart Fail. 2024;11(2):1249\u201357.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2397_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50996-5","volume":"15","author":"SJ Sun","year":"2024","unstructured":"Sun SJ, Jiao XD, Chen ZG, Cao Q, Zhu JH, Shen QR, et al. Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation. Nat Commun. 2024;15(1):6640.","journal-title":"Nat Commun"},{"issue":"1","key":"2397_CR99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","volume":"41","author":"S Epelman","year":"2014","unstructured":"Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014;41(1):21\u201335.","journal-title":"Immunity"},{"issue":"8","key":"2397_CR100","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41591-018-0059-x","volume":"24","author":"G Bajpai","year":"2018","unstructured":"Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, et al. The human heart contains distinct macrophage subsets with divergent origins and functions. Nat Med. 2018;24(8):1234\u201345.","journal-title":"Nat Med"},{"issue":"2","key":"2397_CR101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCRESAHA.118.314028","volume":"124","author":"G Bajpai","year":"2019","unstructured":"Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, et al. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res. 2019;124(2):263\u201378.","journal-title":"Circ Res"},{"issue":"23","key":"2397_CR102","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/eurheartj\/ehu225","volume":"36","author":"F Leuschner","year":"2015","unstructured":"Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, et al. Silencing of CCR2 in myocarditis. Eur Heart J. 2015;36(23):1478\u201388.","journal-title":"Eur Heart J"},{"issue":"5","key":"2397_CR103","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","volume":"136","author":"YV Huang","year":"2025","unstructured":"Huang YV, Sun Y, Chou H, Wagner N, Vitale MR, Bayer AL, et al. Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis. Circ Res. 2025;136(5):473\u201390.","journal-title":"Circ Res"},{"issue":"4","key":"2397_CR104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu H, Galdos FX, Lee D, Waliany S, Huang YV, Ryan J, et al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation. 2022;146(4):316\u201335.","journal-title":"Circulation"},{"key":"2397_CR105","unstructured":"Munir AZ, Gutierrez A, Krawiec CJ, Manandhar P, Shyani AC, Ma P, Gougis P, Baylis RA, Hou L, Remold-O\u2019Donnell E, Balko JM et al. CXCR6(+) t cells drive immune checkpoint inhibitor myocarditis. Circulation. 2026."},{"issue":"12","key":"2397_CR106","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/cvr\/cvae133","volume":"120","author":"J Yu","year":"2024","unstructured":"Yu J, Long B, Li Z, Tian X, Li D, Long J, et al. Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis. Cardiovasc Res. 2024;120(12):1442\u201355.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"2397_CR107","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik A, Somarribas Patterson LF, \u00d6zt\u00fcrk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020;182(5):1252-1270.e34.","journal-title":"Cell"},{"issue":"2","key":"2397_CR108","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41590-024-02062-x","volume":"26","author":"X Chen","year":"2025","unstructured":"Chen X, Ghanizada M, Mallajosyula V, Sola E, Capasso R, Kathuria KR, et al. Differential roles of human CD4+ and CD8+ regulatory T cells in controlling self-reactive immune responses. Nat Immunol. 2025;26(2):230\u20139.","journal-title":"Nat Immunol"},{"issue":"4","key":"2397_CR109","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345\u201352.","journal-title":"Nat Immunol"},{"issue":"5","key":"2397_CR110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775\u201387.","journal-title":"Cell"},{"key":"2397_CR111","doi-asserted-by":"crossref","unstructured":"Blanco-Dom\u00ednguez R, de la Fuente H, Rodr\u00edguez C, Mart\u00edn-Aguado L, S\u00e1nchez-D\u00edaz R, Jim\u00e9nez-Alejandre R, Rodr\u00edguez-Arabaolaza I, Curtabbi A, Garc\u00eda-Guimaraes MM, Vera A, Rivero et al. CD69 expression on regulatory T cells protects from immune damage after myocardial infarction. J Clin Invest 2022;132(21).","DOI":"10.1172\/JCI152418"},{"issue":"1","key":"2397_CR112","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCRESAHA.111.243170","volume":"110","author":"DJ Marchant","year":"2012","unstructured":"Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1):126\u201344.","journal-title":"Circ Res"},{"key":"2397_CR113","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Zhou H, Liu Q, Cheng P, Zhao T, Yang T, et al. Targeting regulatory T cells for cardiovascular diseases. Front Immunol. 2023;14:1126761.","journal-title":"Front Immunol"},{"issue":"2","key":"2397_CR114","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","volume":"174","author":"CJ Workman","year":"2005","unstructured":"Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol. 2005;174(2):688\u201395.","journal-title":"J Immunol"},{"issue":"4","key":"2397_CR115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"CT Huang","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503\u201313.","journal-title":"Immunity"},{"issue":"4","key":"2397_CR116","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/CIRCULATIONAHA.119.043545","volume":"142","author":"X Hua","year":"2020","unstructured":"Hua X, Hu G, Hu Q, Chang Y, Hu Y, Gao L, et al. Single-cell RNA sequencing to dissect the immunological network of autoimmune myocarditis. Circulation. 2020;142(4):384\u2013400.","journal-title":"Circulation"},{"issue":"1","key":"2397_CR117","doi-asserted-by":"crossref","first-page":"2512645","DOI":"10.1080\/21645515.2025.2512645","volume":"21","author":"L Xu","year":"2025","unstructured":"Xu L, Chen Y, Xiong L, Shen Y, Zhou Z, Wang S, et al. A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers. Hum Vaccin Immunother. 2025;21(1):2512645.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2397_CR118","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","volume":"208","author":"T Okazaki","year":"2011","unstructured":"Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208(2):395\u2013407.","journal-title":"J Exp Med"},{"issue":"6","key":"2397_CR119","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bph.15984","volume":"180","author":"TG Gergely","year":"2023","unstructured":"Gergely TG, Kucsera D, T\u00f3th VE, Kov\u00e1cs T, Sayour NV, Drobni ZD, et al. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol. 2023;180(6):740\u201361.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"2397_CR120","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41577-025-01149-2","volume":"25","author":"W Piao","year":"2025","unstructured":"Piao W, Lee ZL, Zapas G, Wu L, Jewell CM, Abdi R, et al. Regulatory T cell and endothelial cell crosstalk. Nat Rev Immunol. 2025;25(8):588\u2013607.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2397_CR121","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/CIRCRESAHA.125.325496","volume":"136","author":"SK Mohanta","year":"2025","unstructured":"Mohanta SK, Heron C, Klaus-Bergmann A, Horstmann H, Brakenhielm E, Giannarelli C, et al. Metabolic and immune crosstalk in cardiovascular disease. Circ Res. 2025;136(11):1433\u201353.","journal-title":"Circ Res"},{"issue":"18","key":"2397_CR122","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007;116(18):2062\u201371.","journal-title":"Circulation"},{"issue":"1","key":"2397_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06551-x","volume":"23","author":"B Sun","year":"2025","unstructured":"Sun B, Xun Z, Zhou Z, Zhang N, Piao M, Li C, et al. Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+\u2009fibroblasts and ACKR1+\u2009endothelial cells in immune-related myocarditis. J Transl Med. 2025;23(1):555.","journal-title":"J Transl Med"},{"key":"2397_CR124","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.326145","author":"LS Tombor","year":"2025","unstructured":"Tombor LS, Lautenschl\u00e4ger T, Glaser SF, Fischer A, Merten M, Hille S, et al. Immunoregulatory endothelial cells interact with T cells after myocardial infarction. Circ Res. 2025. https:\/\/doi.org\/10.1161\/CIRCRESAHA.125.326145.","journal-title":"Circ Res"},{"key":"2397_CR125","first-page":"100289","volume":"11","author":"TD Arthur","year":"2025","unstructured":"Arthur TD, Joshua IN, Nguyen JP, D\u2019Antonio-Chronowska A, D\u2019Antonio M, Frazer KA. IFN\u03b3 activates an immune-like regulatory network in the cardiac vascular endothelium. J Mol Cell Cardiol Plus. 2025;11:100289.","journal-title":"J Mol Cell Cardiol Plus"},{"key":"2397_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cells14171397","author":"S Conte","year":"2025","unstructured":"Conte S, Firoaguer I, Lledo S, Tran TT, El Yazidi C, Simoncini S, et al. Distinct inflammatory responses of hiPSC-derived endothelial cells and cardiomyocytes to cytokines involved in immune checkpoint inhibitor-associated myocarditis. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14171397.","journal-title":"Cells"},{"issue":"21","key":"2397_CR127","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","volume":"136","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation. 2017;136(21):1989\u201392.","journal-title":"Circulation"},{"issue":"4","key":"2397_CR128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124059","volume":"10","author":"B Baban","year":"2015","unstructured":"Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153. PLoS ONE. 2015;10(4):e0124059.","journal-title":"PLoS ONE"},{"issue":"8038","key":"2397_CR129","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-024-08008-5","volume":"635","author":"JM Amrute","year":"2024","unstructured":"Amrute JM, Luo X, Penna V, Yang S, Yamawaki T, Hayat S, et al. Targeting immune-fibroblast cell communication in heart failure. Nature. 2024;635(8038):423\u201333.","journal-title":"Nature"},{"issue":"8038","key":"2397_CR130","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-024-08085-6","volume":"635","author":"M Alexanian","year":"2024","unstructured":"Alexanian M, Padmanabhan A, Nishino T, Travers JG, Ye L, Pelonero A, et al. Chromatin remodelling drives immune cell-fibroblast communication in heart failure. Nature. 2024;635(8038):434\u201343.","journal-title":"Nature"},{"issue":"8","key":"2397_CR131","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s44161-022-00116-7","volume":"1","author":"N Ngwenyama","year":"2022","unstructured":"Ngwenyama N, Kaur K, Bugg D, Theall B, Aronovitz M, Berland R, et al. Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction. Nat Cardiovasc Res. 2022;1(8):761\u201374.","journal-title":"Nat Cardiovasc Res"},{"issue":"3","key":"2397_CR132","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s44161-024-00432-0","volume":"3","author":"C Perez-Shibayama","year":"2024","unstructured":"Perez-Shibayama C, Gil-Cruz C, Cadosch N, L\u00fctge M, Cheng H-W, De Martin A, et al. Bone morphogenic protein-4 availability in the cardiac microenvironment controls inflammation and fibrosis in autoimmune myocarditis. Nat Cardiovasc Res. 2024;3(3):301\u201316.","journal-title":"Nat Cardiovasc Res"},{"issue":"7937","key":"2397_CR133","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326.","journal-title":"Nature"},{"issue":"24","key":"2397_CR134","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"2397_CR135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.amjms.2021.04.018","volume":"362","author":"T Barry","year":"2021","unstructured":"Barry T, Gallen R, Freeman C, Agasthi P, Pedrotty D, Yang M, et al. Successful treatment of steroid-refractory checkpoint inhibitor myocarditis with globulin derived-therapy: a case report and literature review. Am J Med Sci. 2021;362(4):424\u201332.","journal-title":"Am J Med Sci"},{"issue":"24","key":"2397_CR136","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","volume":"380","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Buhlaiga N, Thebault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375\u20136.","journal-title":"N Engl J Med"},{"key":"2397_CR137","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244334","author":"C Wakefield","year":"2021","unstructured":"Wakefield C, Shultz C, Patel B, Malla M. Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report. BMJ Case Rep. 2021. https:\/\/doi.org\/10.1136\/bcr-2021-244334.","journal-title":"BMJ Case Rep"},{"issue":"5","key":"2397_CR138","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315.","journal-title":"Cancer Discov"},{"issue":"2","key":"2397_CR139","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","volume":"118","author":"JE Salem","year":"2025","unstructured":"Salem JE, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al. Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118(2):106\u201315.","journal-title":"Arch Cardiovasc Dis"},{"issue":"16_suppl","key":"2397_CR140","doi-asserted-by":"crossref","first-page":"TPS2680","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2680","volume":"41","author":"KL Reynolds","year":"2023","unstructured":"Reynolds KL, Zlotoff DA, Mooradian M, Zubiri L, Ridker P, Neilan TG. Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis. J Clin Oncol. 2023;41(16_suppl):TPS2680.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2397_CR141","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.tcb.2022.11.001","volume":"33","author":"C Chen","year":"2023","unstructured":"Chen C, Xu P. Cellular functions of cGAS-STING signaling. Trends Cell Biol. 2023;33(8):630\u201348.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"2397_CR142","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133.","journal-title":"Mol Cancer"},{"issue":"6","key":"2397_CR143","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cell.2019.01.016","volume":"176","author":"J Dai","year":"2019","unstructured":"Dai J, Huang YJ, He X, Zhao M, Wang X, Liu ZS, et al. Acetylation blocks cGAS activity and inhibits self-DNA-induced autoimmunity. Cell. 2019;176(6):1447-1460.e14.","journal-title":"Cell"},{"issue":"11","key":"2397_CR144","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1021\/acs.jmedchem.1c00398","volume":"64","author":"J Tan","year":"2021","unstructured":"Tan J, Wu B, Chen T, Fan C, Zhao J, Xiong C, et al. Synthesis and pharmacological evaluation of tetrahydro-\u03b3-carboline derivatives as potent anti-inflammatory agents targeting cyclic GMP-AMP synthase. J Med Chem. 2021;64(11):7667\u201390.","journal-title":"J Med Chem"},{"issue":"6","key":"2397_CR145","doi-asserted-by":"publisher","first-page":"e53932","DOI":"10.15252\/embr.202153932","volume":"23","author":"J Gao","year":"2022","unstructured":"Gao J, Zheng M, Wu X, Zhang H, Su H, Dang Y, et al. CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. EMBO Rep. 2022;23(6):e53932.","journal-title":"EMBO Rep"},{"issue":"7713","key":"2397_CR146","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","volume":"559","author":"SM Haag","year":"2018","unstructured":"Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559(7713):269\u201373.","journal-title":"Nature"},{"key":"2397_CR147","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105465118","author":"Z Hong","year":"2021","unstructured":"Hong Z, Mei J, Li C, Bai G, Maimaiti M, Hu H, et al. STING inhibitors target the cyclic dinucleotide binding pocket. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2105465118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2397_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103323","author":"L Motedayen Aval","year":"2020","unstructured":"Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9103323.","journal-title":"J Clin Med"},{"issue":"12","key":"2397_CR149","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-16-0104","volume":"4","author":"E Moore","year":"2016","unstructured":"Moore E, Clavijo PE, Davis R, Cash H, Van Waes C, Kim Y, et al. Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol Res. 2016;4(12):1061\u201371.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2397_CR150","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2567.2010.03384.x","volume":"132","author":"A Korniejewska","year":"2011","unstructured":"Korniejewska A, McKnight AJ, Johnson Z, Watson ML, Ward SG. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology. 2011;132(4):503\u201315.","journal-title":"Immunology"},{"key":"2397_CR151","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1038\/ncomms8458","volume":"6","author":"ME Mikucki","year":"2015","unstructured":"Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458.","journal-title":"Nat Commun"},{"issue":"1","key":"2397_CR152","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41421-023-00617-0","volume":"9","author":"H Jiao","year":"2023","unstructured":"Jiao H, Pang B, Chiang Y-C, Chen Q, Pan Q, Ren R, et al. Structure basis for the modulation of CXC chemokine receptor 3 by antagonist AMG487. Cell Discov. 2023;9(1):119.","journal-title":"Cell Discov"},{"issue":"11","key":"2397_CR153","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/ijc.24665","volume":"125","author":"E Pradelli","year":"2009","unstructured":"Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer. 2009;125(11):2586\u201394.","journal-title":"Int J Cancer"},{"issue":"1","key":"2397_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02449-1","volume":"11","author":"TYH Chan","year":"2025","unstructured":"Chan TYH, Chen B, Tang W, Chan HH, Wong YKH, Wong ECL, et al. Non-immune targeting of CXCR3 compromises mitochondrial function and suppresses tumor growth in glioblastoma. Cell Death Discov. 2025;11(1):143.","journal-title":"Cell Death Discov"},{"issue":"2","key":"2397_CR155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1189\/jlb.0602269","volume":"73","author":"P Gao","year":"2003","unstructured":"Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003;73(2):273\u201380.","journal-title":"J Leukoc Biol"},{"issue":"8","key":"2397_CR156","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/j.1476-5381.2009.00528.x","volume":"158","author":"J Ni","year":"2009","unstructured":"Ni J, Zhu YN, Zhong XG, Ding Y, Hou LF, Tong XK, et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br J Pharmacol. 2009;158(8):2046\u201356.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"2397_CR157","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/intimm\/dxh284","volume":"17","author":"H Tokuyama","year":"2005","unstructured":"Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, et al. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol. 2005;17(8):1023\u201334.","journal-title":"Int Immunol"},{"key":"2397_CR158","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1351655","volume":"15","author":"AS Chernov","year":"2024","unstructured":"Chernov AS, Rodionov MV, Kazakov VA, Ivanova KA, Meshcheryakov FA, Kudriaeva AA, et al. CCR5\/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome. Front Pharmacol. 2024;15:1351655.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2397_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49613-z","volume":"9","author":"MJ Kim","year":"2019","unstructured":"Kim MJ, Sun HJ, Song YS, Yoo S-K, Kim YA, Seo J-S, et al. CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer. Sci Rep. 2019;9(1):13288.","journal-title":"Sci Rep"},{"issue":"1","key":"2397_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37727-y","volume":"14","author":"B Palakurthi","year":"2023","unstructured":"Palakurthi B, Fross SR, Guldner IH, Aleksandrovic E, Liu X, Martino AK, et al. Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. Nat Commun. 2023;14(1):2109.","journal-title":"Nat Commun"},{"key":"2397_CR161","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003100","author":"B Wang","year":"2021","unstructured":"Wang B, Wang Y, Sun X, Deng G, Huang W, Wu X, et al. CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003100.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"2397_CR162","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","volume":"184","author":"M Di Pilato","year":"2021","unstructured":"Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184(17):4512-4530.e22.","journal-title":"Cell"},{"key":"2397_CR163","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvag151","author":"Y Kametani","year":"2026","unstructured":"Kametani Y, Obana M, Umeda A, Suzuki S, Egawa K, Nishinaka K, et al. YAP plays a critical role in myocardial recovery from myocarditis by suppressing IFN-\u03b3 signalling pathway. Cardiovasc Res. 2026. https:\/\/doi.org\/10.1093\/cvr\/cvag151.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2397_CR164","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41392-025-02143-9","volume":"10","author":"H Li","year":"2025","unstructured":"Li H, Chen X, Wang JJ, Shen J, Abuduwufuer K, Zhang Z, et al. Spatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis. Signal Transduct Target Ther. 2025;10(1):59.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2397_CR165","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2397_CR166","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","volume":"44","author":"TW Stone","year":"2023","unstructured":"Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023;44(7):442\u201356.","journal-title":"Trends Pharmacol Sci"},{"key":"2397_CR167","volume":"156","author":"X He","year":"2025","unstructured":"He X, Zhang J, Zhang Y, Li H, Chen Y, Zhang H, et al. L-Kynurenine regulates immune response in ICIs-associated myocarditis via JAK\/STAT pathway. Int Immunopharmacol. 2025;156:114676.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2397_CR168","volume":"17","author":"EB Cone","year":"2022","unstructured":"Cone EB, Haeuser L, Reese SW, Marchese M, Nguyen DD, Nabi J, et al. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE. 2022;17(11):e0272022.","journal-title":"PLoS ONE"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02397-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:20:02Z","timestamp":1792272002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02397-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":168,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2397"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02397-1","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"247"}}